Gilead is letting go of 34 employees at its Oceanside, California, site.
All entries for: Chronic Disease
January 12, 2026
InflaRx
Discontinued Research, Layoffs
Jena, Germany
51-200 employees
InflaRx is cutting approximately 30% of its employees in a bid to streamline its spending and pour more of its resources into its lead candidate. To accompany the layoffs, InflaRx will also pull money from its investigational antibody Gohibic, according to a press announcement Jan. 8.
Disease Area: Chronic Disease, Immune Diseases, Infectious Diseases
Drug Type: Biologic, Small Molecule
January 8, 2026
Tessera Therapeutics
Layoffs
Somerville, MA
201-500 employees
A month after announcing a partnership with Regeneron to advance its lead gene editor, Tessera Therapeutics has disclosed it will lay off 90 employees. Endpoints News first reported the cuts. Several employees told Endpoints the layoffs will affect about 35% of the workforce. The cuts follow a 17% reduction in 2025 and 13% downsizing in 2024.
Disease Area: Chronic Disease, Multiple, Rare Diseases, Respiratory Diseases
Drug Type: Biologic
November 13, 2025
Fate Therapeutics
Neutral Outlook
San Diego, CA
51-200 employees
The Inflation Reduction Act of 2022 (the IRA), for example, includes several provisions that may impact our business to varying degrees, including provisions that reduce the out-of-pocket spending cap for Medicare Part D beneficiaries to $2,000 starting in 2025, eliminating the prescription drug coverage gap; impose new manufacturer financial liability on certain drugs under Medicare Part D; allow the U.S. government to negotiate Medicare Part B and Part D price caps for certain high-cost drugs and biologics without generic or biosimilar competition; require companies to pay rebates to Medicare for certain drug prices that increase faster than inflation; and delay until January 1, 2032 the implementation of an HHS rebate rule that would have limited the fees that pharmacy benefit managers can charge.
Disease Area: Chronic Disease, Immune Diseases, Oncology, Rare Diseases
Drug Type: Biologic, Small Molecule
November 12, 2025
CalciMedica, Inc.
Neutral Outlook
La Jolla, California
1-50 employees
For example, the Inflation Reduction Act (IRA) passed by Congress authorizes the Secretary of the Department of HHS to negotiate prices directly with participating manufacturers for selected medicines covered by Medicare even if these medicines are protected by an existing patent. For small molecule medicines, the process begins seven years after initial approval by the FDA. While we do not believe that the IRA or its effects will impact our ability to obtain patents in the near future, we cannot be certain whether it will affect our patent strategy in the long run.
Disease Area: Chronic Disease, Gastrointestinal, Immune Diseases, Multiple, Respiratory Diseases
Drug Type: Biologic, Small Molecule
November 12, 2025
Zenas Biopharma
Neutral Outlook
Waltham, MA
51-200 employees
Notably, the Inflation Reduction Act of 2022 (the “IRA”) includes a number of healthcare reform provisions, which have varying implementation dates. The IRA extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025
Disease Area: Chronic Disease, Immune Diseases, Neurological Diseases
Drug Type: Biologic
November 12, 2025
Kalaris Therapeutics
Negative Outlook
Palo Alto, CA
1-50 employees
Further, with the passage of the Inflation Reduction Act (the “IRA”) in August 2022, Congress extended the expansion of ACA premium tax credits through 2025. These and other laws may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain for any of our products or product candidates for which we may obtain regulatory approval or the frequency with which any such product is prescribed or used.
Disease Area: Chronic Disease, Multiple, Neurological Diseases, Rare Diseases
Drug Type: Biologic
November 10, 2025
Akebia Therapeutics, Inc.
Neutral Outlook
Cambridge, MA
201-500 employees
On August 16, 2022, the Inflation Reduction Act of 2022, or IRA, was signed into law by President Biden. The legislation has implications for Medicare Part D, which is a program available to individuals who are entitled to Medicare Part A or enrolled in Medicare Part B to give them the option of paying a monthly premium for outpatient prescription drug coverage. Among other things, the IRA imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation (first due in 2023); and replaces the Part D coverage gap discount program with a new discounting program (beginning in 2025).
Disease Area: Chronic Disease, Hematology, Multiple
Drug Type: Small Molecule